ITCI Intra-Cellular Therapies Inc.

12.48
+0.22  (+2%)
Previous Close 12.26
Open 12.22
Price To Book 2.17
Market Cap 687856903
Shares 55,116,739
Volume 282,883
Short Ratio
Av. Daily Volume 310,897

NewsSee all news

  1. Intra-Cellular Therapies Mourns the Passing of Co-Founder and Nobel Laureate, Dr. Paul Greengard
  2. Intra-Cellular Therapies Presents Additional Results From Long-term Open Label Safety Study of Lumateperone at the 2019 Congress of the Schizophrenia International Research Society
  3. Investors Who Bought Intra-Cellular Therapies (NASDAQ:ITCI) Shares Three Years Ago Are Now Down 61%
  4. Intra-Cellular Therapies Continues to Strengthen Its Commercial Leadership Team; John A. Bardi Appointed as Senior Vice President, Market Access, Policy and Government Affairs
  5. Intra-Cellular Therapies to Present at The Cowen and Company 39th Annual Health Care Conference

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data due 2Q 2019.
ITI-007 - Monotherapy (Study 401)
Bipolar depression
Phase 3 interim analysis December 18, 2018 noted trial to stop due to futility.
ITI-007-201
Agitation in patients with dementia
PDUFA date September 27, 2019.
Lumateperone
Schizophrenia
Phase 3 enrollment to be completed 2H 2019.
ITI-007 - Adjunctive Therapy
Bipolar depression
Phase 3 top-line data due 2Q 2019.
ITI-007 - Monotherapy (Study 404)
Bipolar depression
Phase 1/2 top-line presented October 22, 2018.
ITI-214
Parkinson's disease (PD)

Latest News

  1. Intra-Cellular Therapies Mourns the Passing of Co-Founder and Nobel Laureate, Dr. Paul Greengard
  2. Intra-Cellular Therapies Presents Additional Results From Long-term Open Label Safety Study of Lumateperone at the 2019 Congress of the Schizophrenia International Research Society
  3. Investors Who Bought Intra-Cellular Therapies (NASDAQ:ITCI) Shares Three Years Ago Are Now Down 61%
  4. Intra-Cellular Therapies Continues to Strengthen Its Commercial Leadership Team; John A. Bardi Appointed as Senior Vice President, Market Access, Policy and Government Affairs
  5. Intra-Cellular Therapies to Present at The Cowen and Company 39th Annual Health Care Conference
  6. Edited Transcript of ITCI earnings conference call or presentation 27-Feb-19 1:30pm GMT
  7. Intra-Cellular Therapies Inc (ITCI) Q4 2018 Earnings Conference Call Transcript
  8. Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
  9. Intra-Cellular Therapies to Present at the 8th Annual SVB Leerink Global Healthcare Conference
  10. Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast
  11. Detailed Research: Economic Perspectives on Tesla, Kura Oncology, ASML Holding N.V, Applied Industrial Technologies, Raven Industries, and Intra-Cellular Therapies — What Drives Growth in Today's Competitive Landscape
  12. Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst
  13. Read This Before Buying Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares
  14. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intra-Cellular Therapies, Inc. - ITCI
  15. Intra-Cellular Therapies to Present at the 37th Annual J.P. Morgan Healthcare Conference
  16. Is Intra-Cellular Therapies Inc (ITCI) A Good Stock To Buy?
  17. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Intra-Cellular Therapies, Inc. (ITCI)